ArticleClinical and experimental reproductive medicine2025
Does coenzyme Q10 supplementation protect spermatogenesis in ciprofloxacin-induced rat testes?
Article in Clinical and experimental reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does coenzyme Q10 protect testicular function and spermatogenesis in rats receiving levofloxacin-containing therapy?Clinical and experimental reproductive medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveCiprofloxacin (CPFX) is frequently prescribed by fertility specialists and urologists to manage infections in male reproductive organs. However, it is toxic to the testicles and can lead to infertility. Dietary antioxidants are known to protect the testis from damage. This study aimed to investigate the effects of coenzyme Q10 (CoQ10) on the adverse side effects of CPFX using stereological methods.
methodsSixty rats were divided into six groups: control (distilled water), CoQ10 (10 mg/kg/day), and low-dose (103 mg/kg/day) and high-dose (206 mg/kg/day) of CPFX (LD-CPFX, HD-CPFX) with or without CoQ10 consumption. The treatments lasted for 45 days. Sperm count, serum testosterone levels, and testicular parameters were evaluated.
resultsSignificant decreases in sperm count, motility, normal morphology, viability, and testosterone levels were observed in the LD-CPFX (p<0.003) and HD-CPFX- treated rats (p=0.0001) compared to the control groups. A 10% to 36% reduction in the volume of seminiferous tubules, tubular epithelium, and tubule length was noted in LD-CPFX (p<0.01) and HD-CPFX-treated rats (p<0.006), while the volume of the interstitium increased by 25% to 28% in LD-CPFX (p=0.03) and HD-CPFX (p=0.008) groups. The number of cells, including spermatogonia, spermatocytes, spermatids, Sertoli cells, and Leydig cells, decreased by 36% to 75% in the testes exposed to LD-CPFX (p<0.04) and HD-CPFX (p<0.01), compared to the control groups. However, these changes normalized in rats that received CoQ10.
conclusionCPFX exposure for 45 days, regardless of the dose, has detrimental effects on testicular parameters. CoQ10 can prevent CPFX-induced testicular structural impairments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.